Oct 16 (Reuters) - Sartorius Ag - :9 months business performance of Bioprocess solutions division in 2017 temporary weaker than expected .Key figures on 9-month business development in 2017.Full-year 2017 guidance adjusted.Mid-term outlook and targets remain unchanged.For first nine months of 2017, Sartorius group achieved revenue growth of 8.6% in constant currencies to about 1.04 billion euros.For first nine months of 2017, Sartorius group achieved an underlying EBIDTA margin of 24.8% versus 9 month 2016 25.0%.Sartorius group now expects that sales revenue in constant currencies will increase by approx. 9% for full-year of 2017.Underlying EBIDTA margin in constant currencies now projected to reach approx. Prior-Year level of around 25.0% for FY 2017.
Sept 28 (Reuters) - Quidel Corp ::QUIDEL ANNOUNCES EARLY TERMINATION OF THE HART-SCOTT-RODINO WAITING PERIOD FOR ITS PENDING ACQUISITION OF ALERE’S TRIAGE® B-TYPE NATURIETIC PEPTIDE (BNP) ASSAY BUSINESS RUN ON BECKMAN COULTER ANALYZERS.QUIDEL-GETS NOTICE FROM FTC GRANTING EARLY TERMINATION OF WAITING PERIOD UNDER HART-SCOTT-RODINO ACT FOR CO'S PENDING ACQUISITION OF ALERE'S ASSAY BUSINESS.QUIDEL - CO'S ACQUISITION OF ALERE'S TRIAGE METERPRO BUSINESS IS NOT AFFECTED BY EARLY TERMINATION OF WAITING PERIOD UNDER HART-SCOTT-RODINO.
Sept 27 (Reuters) - Evolent Health Inc :Evolent Health announces proposed expansion of relationships in Illinois and New Mexico.Evolent Health-Evolent's combined administrative services revenue for contracting with both entities is expected to be approximately $20 million in 2018.Evolent Health -in New Mexico, co entered unique agreement to acquire assets of commercial business from New Mexico Health Connections for $10.25 million in cash.Evolent Health Inc says NMHC will continue to operate as an independent non-profit health care organization operating throughout state of New Mexico.